Sameen Khalid1, Aamer Abbass1, Neelam Khetpal1, Bo Shen2, Udayakumar Navaneethan3. 1. Department of Internal Medicine, Advent Health, Orlando, FL, USA. 2. Department of Gastroenterology, Cleveland Clinic, Cleveland, OH, USA. 3. Center for Interventional Endoscopy, Advent Health, University of Central Florida College of Medicine, 601 E Rollins Street, Orlando, FL, 32803, USA. udhaykumar81@gmail.com.
Abstract
BACKGROUND: Patients with ulcerative colitis and Crohn's colitis have an increased risk of developing dysplasia and colorectal cancer as compared to the general population; surveillance colonoscopy is recommended in this patient population. METHODS: This review of the published literature aimed to assess the published evidence. RESULTS: Detection of dysplasia requires examination of mucosa with targeted biopsies of the visible lesions as well as random biopsies to detect invisible lesions. Newer endoscopic techniques, in particular chromoendoscopy, increase the yield of identifying dysplastic lesions. The surveillance for Colorectal Endoscopic Neoplasia Detection and Management in Inflammatory Bowel Disease Patients International Consensus (SCENIC) guidelines recommends that colonoscopy using chromoendoscopy is the optimal endoscopic surveillance strategy to detect dysplasia. Once dysplastic lesions are discovered on surveillance endoscopic examination, careful and meticulous descriptions of lesions is mandatory to aid in further decision making. Management of dysplastic lesions in inflammatory bowel disease patients depends on endoscopic (morphological) and histologic findings and patient characteristics such as age, general condition of the patient, and patient preferences. Endoscopic mucosal resection, endoscopic submucosal dissection, and surgery are different therapeutic options for colonic dysplastic lesions detected in the setting of inflammatory bowel disease. CONCLUSIONS: In this review, we discuss the various techniques for endoscopic resection of dysplasia in patients with inflammatory bowel disease. Further research is required to determine the optimal approach to diagnosis and management of dysplasia in patients with inflammatory bowel disease.
BACKGROUND:Patients with ulcerative colitis and Crohn's colitis have an increased risk of developing dysplasia and colorectal cancer as compared to the general population; surveillance colonoscopy is recommended in this patient population. METHODS: This review of the published literature aimed to assess the published evidence. RESULTS: Detection of dysplasia requires examination of mucosa with targeted biopsies of the visible lesions as well as random biopsies to detect invisible lesions. Newer endoscopic techniques, in particular chromoendoscopy, increase the yield of identifying dysplastic lesions. The surveillance for Colorectal Endoscopic Neoplasia Detection and Management in Inflammatory Bowel DiseasePatients International Consensus (SCENIC) guidelines recommends that colonoscopy using chromoendoscopy is the optimal endoscopic surveillance strategy to detect dysplasia. Once dysplastic lesions are discovered on surveillance endoscopic examination, careful and meticulous descriptions of lesions is mandatory to aid in further decision making. Management of dysplastic lesions in inflammatory bowel diseasepatients depends on endoscopic (morphological) and histologic findings and patient characteristics such as age, general condition of the patient, and patient preferences. Endoscopic mucosal resection, endoscopic submucosal dissection, and surgery are different therapeutic options for colonic dysplastic lesions detected in the setting of inflammatory bowel disease. CONCLUSIONS: In this review, we discuss the various techniques for endoscopic resection of dysplasia in patients with inflammatory bowel disease. Further research is required to determine the optimal approach to diagnosis and management of dysplasia in patients with inflammatory bowel disease.
Authors: Ralf Kiesslich; Johannes Fritsch; Martin Holtmann; Heinz H Koehler; Manfred Stolte; Stephan Kanzler; Bernhard Nafe; Michael Jung; Peter R Galle; Markus F Neurath Journal: Gastroenterology Date: 2003-04 Impact factor: 22.682
Authors: Nicholas G Burgess; Luke F Hourigan; Simon A Zanati; Gregor J Brown; Rajvinder Singh; Stephen J Williams; Spiro C Raftopoulos; Donald Ormonde; Alan Moss; Karen Byth; Hema Mahajan; Duncan McLeod; Michael J Bourke Journal: Gastroenterology Date: 2017-06-02 Impact factor: 22.682
Authors: Arthur Schmidt; Torsten Beyna; Brigitte Schumacher; Alexander Meining; Hans-Juergen Richter-Schrag; Helmut Messmann; Horst Neuhaus; David Albers; Michael Birk; Robert Thimme; Andreas Probst; Martin Faehndrich; Thomas Frieling; Martin Goetz; Bettina Riecken; Karel Caca Journal: Gut Date: 2017-08-10 Impact factor: 23.059
Authors: Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682